MX2023002650A - Metodos de tratamiento del dolor por cancer mediante la administracion de un inhibidor de pd-1. - Google Patents

Metodos de tratamiento del dolor por cancer mediante la administracion de un inhibidor de pd-1.

Info

Publication number
MX2023002650A
MX2023002650A MX2023002650A MX2023002650A MX2023002650A MX 2023002650 A MX2023002650 A MX 2023002650A MX 2023002650 A MX2023002650 A MX 2023002650A MX 2023002650 A MX2023002650 A MX 2023002650A MX 2023002650 A MX2023002650 A MX 2023002650A
Authority
MX
Mexico
Prior art keywords
patient
inhibitor
administering
methods
cancer
Prior art date
Application number
MX2023002650A
Other languages
English (en)
Inventor
Chieh-I Chen
Medha R Sasane
Denise P Bury-Maynard
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2023002650A publication Critical patent/MX2023002650A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción provee métodos para tratar o inhibir el dolor por cáncer en un paciente que lo necesite, incluida la selección de un paciente con cáncer y la administración al paciente de una cantidad terapéuticamente eficaz de un inhibidor de muerte programada 1 (PD-1). La presente descripción también provee métodos para reducir el uso de analgésicos en un paciente que lo necesite, incluida la selección de un paciente con cáncer y la administración al paciente de una cantidad terapéuticamente eficaz de un inhibidor de PD-1, en donde el paciente está siendo tratado con una terapia con analgésicos de base antes de la administración del inhibidor de PD-1. En algunas modalidades, los métodos descritos conducen al mismo tiempo a la regresión del tumor, la reducción del dolor y la reducción del uso de la terapia con analgésicos.
MX2023002650A 2020-09-03 2021-09-02 Metodos de tratamiento del dolor por cancer mediante la administracion de un inhibidor de pd-1. MX2023002650A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063074282P 2020-09-03 2020-09-03
US202163161519P 2021-03-16 2021-03-16
US202163186375P 2021-05-10 2021-05-10
EP21315132 2021-07-29
PCT/US2021/048785 WO2022051448A1 (en) 2020-09-03 2021-09-02 Methods of treating cancer pain by administering a pd-1 inhibitor

Publications (1)

Publication Number Publication Date
MX2023002650A true MX2023002650A (es) 2023-06-08

Family

ID=77924529

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002650A MX2023002650A (es) 2020-09-03 2021-09-02 Metodos de tratamiento del dolor por cancer mediante la administracion de un inhibidor de pd-1.

Country Status (10)

Country Link
US (1) US11932692B2 (es)
EP (1) EP4208258A1 (es)
JP (1) JP2023542490A (es)
KR (1) KR20230061499A (es)
CN (1) CN116194142A (es)
AU (1) AU2021337650A1 (es)
CA (1) CA3170207A1 (es)
IL (1) IL300975A (es)
MX (1) MX2023002650A (es)
WO (1) WO2022051448A1 (es)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4896327B2 (ja) 1999-08-23 2012-03-14 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド Pd−1、b7−4の受容体、およびその使用
ES2654064T3 (es) 2002-07-03 2024-03-13 Ono Pharmaceutical Co Composiciones inmunopotenciadoras que comprenden anticuerpos anti-PD-L1
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
CN101213297B (zh) 2005-05-09 2013-02-13 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 pd-1에 대한 항체
CA2698419C (en) 2007-09-07 2019-11-12 Edward Dolk Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
MX349463B (es) 2008-09-26 2017-07-31 Univ Emory Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CA2802344C (en) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
RU2604814C2 (ru) 2011-07-24 2016-12-10 Кьюртек Лтд. Варианты гуманизированных иммуномодулирующих моноклональных антител
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
LT2883449T (lt) 2012-03-16 2018-05-10 Regeneron Pharmaceuticals, Inc. Histidinu modifikuoti lengvosios grandinės antikūnai ir juos gaminantys genetiškai modifikuoti graužikai
SG11201407859YA (en) 2012-05-31 2014-12-30 Genentech Inc Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
EP3553086A1 (en) 2012-05-31 2019-10-16 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
CA2956399A1 (en) 2014-08-05 2016-02-11 Cb Therapeutics, Inc. Anti-pd-l1 antibodies
US10336824B2 (en) 2015-03-13 2019-07-02 Cytomx Therapeutics, Inc. Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof
KR20180040138A (ko) 2015-07-13 2018-04-19 싸이톰스 테라퓨틱스, 인크. 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
MX2018012132A (es) 2016-04-07 2019-03-28 Chemocentryx Inc Reduccion de carga tumoral mediante administracion de antagonistas de ccr1 en combinacion con inhibidores de muerte-1 programada (pd-1) o inhibidores de ligando-1 de muerte-1 programada (pd-l1).
TWI755395B (zh) * 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
US11007250B2 (en) 2017-05-12 2021-05-18 Duke University Methods and kits for treating pain
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CN113507963A (zh) 2019-01-21 2021-10-15 赛诺菲 用于晚期实体瘤癌症的治疗性rna及抗pd1抗体

Also Published As

Publication number Publication date
CA3170207A1 (en) 2022-03-10
JP2023542490A (ja) 2023-10-10
US20220064304A1 (en) 2022-03-03
KR20230061499A (ko) 2023-05-08
AU2021337650A1 (en) 2023-05-04
IL300975A (en) 2023-04-01
AU2021337650A9 (en) 2024-06-13
EP4208258A1 (en) 2023-07-12
WO2022051448A1 (en) 2022-03-10
CN116194142A (zh) 2023-05-30
US11932692B2 (en) 2024-03-19

Similar Documents

Publication Publication Date Title
EP4327882A3 (en) Enpp1 inhibitors and their use for the treatment of cancer
MX2023002248A (es) Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
MX2021009269A (es) Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria.
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
ZA202109010B (en) Compounds and methods for the treatment of covid-19
MX2022012992A (es) Inhibidores de kif18a para el tratamiento de enfermedades neoplasicas.
WO2009129509A3 (en) Methods and compositions for treating post-operative pain comprising a local anesthetic
HK1078771A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer
MX2023014028A (es) Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos.
MX2022009091A (es) Anticuerpos para usarse en terapia.
MX2023010657A (es) Inhibidores de los retrotransposones largos intercalados del elemento 1 (line-1) para tratar enfermedades del sistema nervioso central (snc) y sistemicas.
BR112022010806A2 (pt) Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama
BRPI0508982A (pt) uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11
MX2022014356A (es) Ciertas composiciones quimicas y metodos de uso de las mismas.
MX2023003332A (es) Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades.
MX2023002650A (es) Metodos de tratamiento del dolor por cancer mediante la administracion de un inhibidor de pd-1.
TW200724158A (en) Combination therapy in the treatment of cancer
MX2022001450A (es) Metodo de tratamiento del cancer.
EA202290027A1 (ru) Способы и композиции для улучшения результатов лечения пациентов с раком
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
WO2023019095A3 (en) Momelotinib combination therapy
MX2023009279A (es) Metodos de tratamiento de cancer mediante la administracion de un inhibidor de pd-1 como neoadyuvante.
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
BR112023023702A2 (pt) Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.